Aspirin hypersensitivity diagnostic index (AHDI): In vitro test for diagnosing of N-ERD based on urinary 15-oxo-ETE and LTE
15‐oxo‐eicosatetraenoic acid
NSAID‐exacerbated respiratory disease
aspirin hypersensitivity diagnostic index
in‐vitro diagnostic test
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
revised:
22
07
2024
received:
20
12
2023
accepted:
28
07
2024
medline:
24
8
2024
pubmed:
24
8
2024
entrez:
24
8
2024
Statut:
aheadofprint
Résumé
15-oxo-eicosatetraenoic acid (15-oxo-ETE), is a product of arachidonic acid (AA) metabolism in the 15-lipoxygenase-1 (15-LOX-1) pathway. 15-oxo-ETE was overproduced in the nasal polyps of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). In this study we investigated the systemic biosynthesis of 15-oxo-ETE and leukotriene E The study included 64 patients with N-ERD, 59 asthmatics who tolerated aspirin well (ATA), and 51 healthy controls. A thorough clinical characteristics of asthmatics included computed tomography of paranasal sinuses. Plasma and urinary 15-oxo-ETE levels, and urinary LTE Plasma 15-oxo-ETE levels were the highest in N-ERD (p < .001). A receiver operator characteristic (ROC) revealed that 15-oxo-ETE had certain sensitivity (64.06% in plasma, or 88.24% in urine) for N-ERD discrimination, while the specificity was rather limited. Modeling of variables allowed to construct the Aspirin Hypersensitivity Diagnostic Index (AHDI) based on urinary LTE We confirmed 15-oxo-ETE as a second to cysteinyl leukotrienes biomarker of N-ERD. An index based on these eicosanoids corrected for sex and Lund-Mackay score has a similar diagnostic value as gold standard oral aspirin challenge in the studied group of patients with asthma.
Sections du résumé
BACKGROUND
BACKGROUND
15-oxo-eicosatetraenoic acid (15-oxo-ETE), is a product of arachidonic acid (AA) metabolism in the 15-lipoxygenase-1 (15-LOX-1) pathway. 15-oxo-ETE was overproduced in the nasal polyps of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). In this study we investigated the systemic biosynthesis of 15-oxo-ETE and leukotriene E
METHODS
METHODS
The study included 64 patients with N-ERD, 59 asthmatics who tolerated aspirin well (ATA), and 51 healthy controls. A thorough clinical characteristics of asthmatics included computed tomography of paranasal sinuses. Plasma and urinary 15-oxo-ETE levels, and urinary LTE
RESULTS
RESULTS
Plasma 15-oxo-ETE levels were the highest in N-ERD (p < .001). A receiver operator characteristic (ROC) revealed that 15-oxo-ETE had certain sensitivity (64.06% in plasma, or 88.24% in urine) for N-ERD discrimination, while the specificity was rather limited. Modeling of variables allowed to construct the Aspirin Hypersensitivity Diagnostic Index (AHDI) based on urinary LTE
CONCLUSIONS
CONCLUSIONS
We confirmed 15-oxo-ETE as a second to cysteinyl leukotrienes biomarker of N-ERD. An index based on these eicosanoids corrected for sex and Lund-Mackay score has a similar diagnostic value as gold standard oral aspirin challenge in the studied group of patients with asthma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Narodowe Centrum Nauki
Informations de copyright
© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Stevens WW, Cahill KN. Mechanistic and clinical updates in AERD:2021–2022. J Allergy Clin Immunol. 2023;151:1448‐1456.
White AA, Stevenson DD. Aspirin‐exacerbated respiratory disease. N Engl J Med. 2018;379:1060‐1070.
Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150:1333‐1393.
Mastalerz L, Celejewska‐Wójcik N, Wójcik K, et al. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. Allergy. 2014;69:1550‐1559.
Mastalerz L, Celejewska‐Wójcik N, Ćmiel A, et al. Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease. Clin Transl Allergy. 2023;13:e12235.
Celejewska‐Wójcik N, Wójcik K, Ignacak‐Popiel M, et al. Subphenotypes of nonsteroidal antiinflammatory disease‐exacerbated respiratory disease identified by latent class analysis. Allergy. 2020;75:831‐840.
Trąd G, Sanak M, Ćmiel A, Celejewska‐Wójcik N, Czekaj M, Mastalerz L. Peripheral biomarkers for predicting sputum eosinophilica in nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease. Allergy. 2023;78:3001‐3003.
Mastalerz L, Tyrak KE, Ignacak M, et al. Prostaglandin E2 decrease in induced sputum of hypersensitive asthmatics during oral challenge with aspirin. Allergy. 2019;74:922‐932.
Celik GE, Erkekol FO, Misirligil Z, Melli M. Lipoxin A4 levels in asthma: relations with disease severity and aspirin sensitivity. Clin Exp Allergy. 2007;37:1494‐1501.
Feng X, Ramsden MK, Negri J, et al. Eosinophil production of prostaglandin D2 in patients with aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2016;138:1089‐1097.
Laidlaw TM, Boyce JA. Updates on immune mechanisms in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2023;151:301‐309.
Wangberg H, White AA. Aspirin‐exacerbated respiratory disease. Curr Opin Immunol. 2020;66:9‐13.
Celik G, Misirligil Z. Lipoxins in asthma. J Allergy Clin Immunol. 2004;114:992.
Stevens WW, Staudacher AG, Hulse KE, et al. Activation of the 15‐lipoxygenase pathway in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147:600‐612.
Jerschow E, Edin ML, Pelletier T, et al. Plasma 15‐hydroxyeicosatetraenoic acid predicts treatment outcomes in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5:998‐1007.
Hagan JB, Laidlaw TM, Divekar R, et al. Urinary leukotriene E4 to determine aspirin intolerance in asthma: a systematic review and meta‐analysis. J Allergy Clin Immunol Pract. 2017;5:990‐997.
White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin‐exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2006;97:190‐195.
Gamboa P, Sanz ML, Caballero MR, et al. The flow‐cytometric determination of basophil activation induced by aspirin and other non‐steroidal anti‐inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy. 2004;34:1448‐1457.
Shin SW, Park JS, Park CS. Elevation of eosinophil‐derived neurotoxin in plasma of the subjects with aspirin‐exacerbated respiratory disease: a possible peripheral blood protein biomarker. PLoS One. 2013;8:e66644.
Kim MA, Izuhara K, Ohta S, et al. Association of serum periostin with aspirin‐exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2014;113:314‐320.
Ban GY, Cho K, Kim SH, et al. Metabolomic analysis identifies potential diagnostic biomarkers for aspirin‐exacerbated respiratory disease. Clin Exp Allergy. 2017;47:37‐47.
Divekar R, Hagan J, Rank M, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract. 2016;4:665‐670.
Tyrak KE, Pajdzik K, Konduracka E, et al. Artificial neural network identifies nonsteroidal anti‐inflammatory drugs exacerbated respiratory disease (N‐ERD) cohort. Allergy. 2020;75:1649‐1658.
Kowalski ML, Ptasińska A, Jędrzejczak M, et al. Aspirin‐triggered 15‐HETE generation in peripheral blood leukocytes is a specific and sensitive aspirin‐sensitive patients identification test (ASPITest). Allergy. 2005;60:1139‐1145.
Niżankowska‐Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/ GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62:1111‐1118.
Mastalerz L, Sanak M. Updates in AERD: what is needed further? J Allergy Clin Immunol. 2023;152:1685‐1686.
Dwyer DF. Eicosanoid relay: epithelial and mast cell transmetabolism in AERD. J Allergy Clin Immunol. 2021;147:501‐503.
2022 GINA Report, Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. Accessed October 9, 2023. https://ginasthma.org/gina‐reports/
Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik A. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:1796‐1800.
Ma G, Pan B, Ren S, et al. 15‐oxoeicosatetraenoic acid mediates monocyte adhesion to endothelial cell. Lipids Health Dis. 2017;16:137.
Smith G. European medicines agency guideline on bioanalytical method validation: what more is there to say? Bioanalysis. 2012;4:865‐868.
Bioanalytical Method Validation Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM). May 2018 Biopharmaceutics. Accessed October 9,2023. https://www.fda.gov/files/drugs/published/Bioanalytical‐Method‐Validation‐Guidance‐for‐Industry.pdf
Tyrak KE, Pajdzik K, Jakieła B, et al. Biomarkers for predicting response to aspirin therapy in aspirin‐exacerbated respiratory disease. Clin Exp Allergy. 2021;51:1046‐1056.
James A, Daham K, Backman L, et al. The influence of aspirin on release of eoxin C4, leukotriene C4 and 15‐HETE, in eosinophilic granulocytes isolated from patients with asthma. Int Arch Allergy Immunol. 2013;162:135‐142.
Takahashi T, Kato A, Berdnikovs S, et al. Microparticles in nasal lavage fluids in chronic rhinosinusitis: potential biomarkers for diagnosis of aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2017;140:720‐729.
Kühn H, O'Donnell VB. Inflammation and immune regulation by 12/15‐lipoxygnase. Prog Lipid Res. 2006;45:334‐356.
Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D2: a dominant mediator of aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:245‐252.
Scott WC, Cahil KN, Milne GL, et al. Inflammatory heterogeneity in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147:1318‐1328.
Haimerl P, Bernhardt U, Schindela S, et al. Inflammatory macrophage memory in nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147:587‐599.
Zhao J, O'Donnell VB, Balzar S, St. Croix CM, Trudeau JB, Wenzel SE. 15‐lipoxygenase 1 interacts with phosphatidylethanolamine‐binding protein to regulate MAPK signaling in human airway epithelial cells. Proc Natl Acad Sci. 2011;108:14246‐14251.
Li Z, Zeng M, Deng Y, et al. 15‐lipoxygenase 1 in nasal polyps promotes CCL26/eotaxin 3 expression through extracellular signal‐regulated kinase activation. J Allergy Clin Immunol. 2019;144:1228‐1241.
Amerio P, Frezzolini A, Feliciani C, et al. Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Curr Drug Targets Inflamm Allergy. 2003;2:81‐94.
Stevens WW, Staudacher AG, Hulse KE, et al. Studies of the role of basophils in aspirin‐exacerbated respiratory disease pathogenesis. J Allergy Clin Immunol. 2021;148:439‐449.
Wangberg H, Bagsic SRS, Osuna L, White AA. Appraisal of the real‐world effectiveness of biologic therapies in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2022;10:478‐484.
Mastalerz L, Kacorzyk R, Jakieła B, Ćmiel A, Sanak M. Sputum transcriptome analysis of co‐regulated genes related to arachidonic acid metabolism in N‐ERD. Allergy. 2023;78:553‐555.
Hastie AT, Mauger DT, Denlinger LC, et al. Mixed sputum granulocyte longitudinal impact on lung function in the severe asthma research program. Am J Respir Crit Care Med. 2021;203:882‐892.
Lee SH, Rngiah K, Williams MV, Wehr AY, DuBois RN, Blair AI. Cyclooxygenase‐2‐mediated metabolism of arachidonic acid to 15‐oxo‐eicosatetraenoic acid by rat intestinal epithelial cells. Chem Res Toxicol. 2007;20:1665‐1675.
Wei C, Zhu P, Shah SJ, Blair IA. 15‐oxo‐Eicosatetraenoic acid, a metabolite of macrophage 15‐hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation. Mol Pharmacol. 2009;76:516‐525.